Stock GLUE MONTE ROSA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Monte Rosa Therapeutics, Inc.

Equities

GLUE

US61225M1027

Real-time Estimate Cboe BZX
Other stock markets
 18:18:34 10/05/2024 BST 		5-day change 1st Jan Change
4.795 USD -7.43% Intraday chart for Monte Rosa Therapeutics, Inc. -14.67% -14.67%
05-09 Monte Rosa Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
05-02 Monte Rosa Therapeutics, Inc. Announces Departure of Owen Wallace as Chief Scientific Officer and Transition to Member of its Scientific Advisory Board CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Monte Rosa Therapeutics : Corporate Presentation - May 2024
PU
Monte Rosa Therapeutics: Q1 Earnings Snapshot
AQ
Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
AQ
Monte Rosa Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer
AQ
Monte Rosa Therapeutics, Inc. Announces Departure of Owen Wallace as Chief Scientific Officer and Transition to Member of its Scientific Advisory Board
CI
UBS Adjusts Monte Rosa Therapeutics Price Target to $20 From $22, Maintains Buy Rating
MT
Monte Rosa Therapeutics : AACR 2024 – The GSPT1 Molecular Glue Degrader MRT-2359 Is Active against Prostate Cancer
PU
Monte Rosa Therapeutics Q4 Net Loss Narrows; Shares Decline
MT
Monte Rosa Therapeutics: Q4 Earnings Snapshot
AQ
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
AQ
Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitor
AQ
Monte Rosa Therapeutics, Inc. Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1b Pathway Inhibitor
CI
Wedbush Starts Monte Rosa Therapeutics With Outperform Rating, $11 Price Target
MT
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
AQ
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024
AQ
Monte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
AQ
Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from NASDAQ Biotechnology Index
CI
Monte Rosa Therapeutics to Present at Piper Sandler Healthcare Conference
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GLUE Stock
  4. News Monte Rosa Therapeutics, Inc.